HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riddle, M. C. Search for Related Content PubMed PubMed Citation Articles by Riddle, M. C. Social Bookmarking                What's this?

Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?

An argument in favor

From the Oregon Health & Science University, Portland, Oregon

Address correspondence and reprint requests to Matthew C. Riddle, MD, Section of Diabetes L-345, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97201. E-mail: riddlem@ohsu.edu

Abbreviations: FPG, fasting plasma glucose

The first 300 words of the full text of this article appear below.

	INTRODUCTION

 
Physicians in many countries use combinations of antihyperglycemic agents to achieve the best glycemic control possible under the conditions faced by individual patients with type 2 diabetes. This widespread use of combined therapies, including oral agents combined with insulin, suggests that the diabetes community accepts the value of this tactic. A routine need for combined therapies was explicitly acknowledged by the investigators in the U.K. Prospective Diabetes Study. Review of the results of 9 years of monotherapy with various agents in the U.K. Prospective Diabetes Study found that fasting plasma glucose (FPG) was kept below 7.8 mmol/l (140 mg/dl) in only 18% of participants using metformin, 24% using a sulfonylurea, and 42% using insulin (1). Corresponding values for keeping A1C below 7% were 13% with metformin, 24% with a sulfonylurea, and 28% with insulin. Regardless of which agent was used as initial therapy, a progressive worsening of glycemic control ensued, largely because of a gradual decline of endogenous insulin production. A substudy embedded in the U.K. Prospective Diabetes Study compared early addition of basal insulin to a sulfonylurea with insulin alone and showed that over 6 years of treatment the combined regimen achieved lower median A1C (6.6 vs. 7.1%) and also less major hypoglycemia (1.6 vs. 3.2% annually) (2). The U.K. Prospective Diabetes Study investigators concluded that "the majority of patients need multiple therapies to attain these glycemic targets in the longer term" (1).

However, combined therapy with oral agents and insulin has not been accepted as desirable by all experts. This article describes an argument in favor of combined therapy in a recent debate examining the advantages and limitations of this approach. Because reports of various combined regimens have been summarized previously, consistently showing better glycemic control with combined therapy (3–. . . [Full Text of this Article]

	PHARMACOLOGIC RATIONALE FOR COMBINED THERAPY

 

	PHYSIOLOGIC ASPECTS OF COMBINED THERAPY

 

	SELECTED CLINICAL TRIALS ILLUSTRATING POTENTIAL BENEFITS

 

	UNANSWERED QUESTIONS

 

	SUMMARY

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Esposito, M. Ciotola, M. I. Maiorino, R. Gualdiero, B. Schisano, A. Ceriello, F. Beneduce, G. Feola, and D. Giugliano Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control: A Randomized Trial Ann Intern Med, October 21, 2008; 149(8): 531 - 539. [Abstract] [Full Text] [PDF]